



*cells*

IMPACT  
FACTOR  
7.666

Indexed in:  
PubMed

an Open Access Journal by MDPI

## BNCT Drug Development and Preclinical Testing

Guest Editors:

**Prof. Dr. Wolfgang Sauerwein**

wolfgang.sauerwein@uni-due.de

**Prof. Dr. Lucie Sancey**

lucie.sancey@univ-grenoble-  
alpes.fr

**Dr. Sunil Krishnan**

krishnan.sunil@mayo.edu

Deadline for manuscript  
submissions:

**30 November 2022**

### Message from the Guest Editors

The appearance of hospital-based epithermal neutron sources has made boron neutron capture therapy (BNCT) a dedicated focus of innovative developments in radiation oncology. This binary treatment modality not only needs neutrons but also a carrier transporting B-10 selectively into cancer cells. This has fueled the quest for new compounds for BNCT and resurgence of interest in preclinical testing of these next-generation compounds.

This Special Issue of *Cells* is dedicated to collating results of recent preclinical research related to the development and testing of novel boron-containing therapeutic compounds and publishing a collection of intelligible and clear reviews of the most challenging aspects of drug development for BNCT. You are invited to submit your contributions in the form of original research articles, reviews, or shorter perspective articles.



[mdpi.com/si/122786](https://mdpi.com/si/122786)

**Special Issue**